A trial failure for the UK-based biopharmaceutical firm Realm Therapeutics (LSE: RLM) has led to its share price dropping to less than half of the level that it started the week at.
The setback in the Phase II trial of PR022 in atopic dermatitis follows the failure of the Phase II program for PR013 in allergic conjunctivitis earlier this year.
In a trial of 120 patients, PR022 showed no difference to the control arm in the primary endpoint of percent change in eczema area severity index.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze